Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 1
2008 2
2009 2
2010 3
2011 5
2012 5
2013 10
2014 8
2015 9
2016 9
2017 11
2018 11
2019 11
2020 9
2021 23
2022 32
2023 38
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for peng bo su
Search for Pengbo Su instead (1 results)
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).
Xu J, Li Y, Fan Q, Shu Y, Yang L, Cui T, Gu K, Tao M, Wang X, Cui C, Xu N, Xiao J, Gao Q, Liu Y, Zhang T, Bai Y, Li W, Zhang Y, Dai G, Ma D, Zhang J, Bai C, Huang Y, Liao W, Wu L, Chen X, Yang Y, Wang J, Ji S, Zhou H, Wang Y, Ma Z, Wang Y, Peng B, Sun J, Mancao C. Xu J, et al. Among authors: peng b. Nat Commun. 2022 Feb 14;13(1):857. doi: 10.1038/s41467-022-28408-3. Nat Commun. 2022. PMID: 35165274 Free PMC article. Clinical Trial.
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3).
Shi Y, Wu L, Yu X, Xing P, Wang Y, Zhou J, Wang A, Shi J, Hu Y, Wang Z, An G, Fang Y, Sun S, Zhou C, Wang C, Ye F, Li X, Wang J, Wang M, Liu Y, Zhao Y, Yuan Y, Feng J, Chen Z, Shi J, Sun T, Wu G, Shu Y, Guo Q, Zhang Y, Song Y, Zhang S, Chen Y, Li W, Niu H, Hu W, Wang L, Huang J, Zhang Y, Cheng Y, Wu Z, Peng B, Sun J, Mancao C, Wang Y, Sun L. Shi Y, et al. Among authors: peng b. Cancer Commun (Lond). 2022 Dec;42(12):1314-1330. doi: 10.1002/cac2.12385. Epub 2022 Nov 6. Cancer Commun (Lond). 2022. PMID: 36336841 Free PMC article. Clinical Trial.
A case report of retroperitoneal Castleman disease.
Bo P, Junhua Z, Qiruo G, Hong L. Bo P, et al. Can Urol Assoc J. 2009 Jun;3(3):E14-E16. doi: 10.5489/cuaj.1099. Can Urol Assoc J. 2009. PMID: 19543453 Free PMC article.
Pathological examination revealed a right retroperitoneal mass of CD (hyaline vascular type). The patient completely recovered after surgery. Castleman disease is commonly misdiagnosed as malignant lymphoma, lymphadenitis or ectopic thymoma. ...
Pathological examination revealed a right retroperitoneal mass of CD (hyaline vascular type). The patient completely recovered after surg …
Cell-based tissue-engineered urethras.
Yang B, Peng B, Zheng J. Yang B, et al. Among authors: peng b. Lancet. 2011 Aug 13;378(9791):568-9; author reply 569. doi: 10.1016/S0140-6736(11)61290-7. Lancet. 2011. PMID: 21840457 No abstract available.
Bioengineered MSC-derived exosomes in skin wound repair and regeneration.
Zhao H, Li Z, Wang Y, Zhou K, Li H, Bi S, Wang Y, Wu W, Huang Y, Peng B, Tang J, Pan B, Wang B, Chen Z, Zhang Z. Zhao H, et al. Among authors: peng b. Front Cell Dev Biol. 2023 Feb 27;11:1029671. doi: 10.3389/fcell.2023.1029671. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 36923255 Free PMC article. Review.
182 results